Von Willebrand Factor in Pregnancy (VIP) Study

This study, called the VIP (Von Willebrand Factor in Pregnancy) Study, is looking at how Von Willebrand Disease (VWD) — a common inherited bleeding disorder — affects women during and after pregnancy. VWD causes problems with blood clotting, which can lead to serious bleeding around the time of childbirth. Normally, pregnancy causes VWF levels to rise and may temporarily correct the disorder, but not all women with VWD experience this correction. The study is tracking pregnant women with VWD to better understand their bleeding risk during delivery and the postpartum period. Women are divided into two groups: those whose VWD naturally corrects during pregnancy, and those whose VWD does not correct. The researchers want to learn how best to prevent and manage serious bleeding in these women. You may be eligible if: - You are a woman diagnosed with Type 1, Type 2, or Type 3 Von Willebrand Disease - You are pregnant and can provide consent before week 39 of pregnancy - Your VWF and Factor VIII levels have been measured between gestational weeks 34–38 You may NOT be eligible if: - You have a known contraindication to the study medications (wilate or tranexamic acid) - You have another bleeding disorder, platelet dysfunction, or collagen disorder - You have liver disease, kidney disease, preeclampsia, HELLP syndrome, or other clotting disorders - You are under 18 years of age - Your local lab cannot perform the required VWF monitoring tests Talk to your doctor to see if this trial is right for you.